Abstract GS5-02: Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial

I. Thune, Anders Husøy, Hanne Frydenberg, V. Flote, F. Fjeldheim, G. F. Bertheussen, S. Lundgren, J. Lømo, E. Wist, A. McTiernan, E. Schlichting
{"title":"Abstract GS5-02: Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial","authors":"I. Thune, Anders Husøy, Hanne Frydenberg, V. Flote, F. Fjeldheim, G. F. Bertheussen, S. Lundgren, J. Lømo, E. Wist, A. McTiernan, E. Schlichting","doi":"10.1158/1538-7445.SABCS18-GS5-02","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer survival rates have improved, but cardiovascular disease is a competing cause of death among breast cancer survivors, and treatment-induced cardio-toxicity remains a major concern. The effect of aerobic exercise on cardiovascular function during adjuvant breast cancer treatment is not yet well established. Material & methods: The women participating in the Energy Balance and Breast Cancer Aspect (EBBA)-II trial are aged 18-75 years and diagnosed with stage I-II breast cancer. VO2max was assessed at three separate times, prior to surgery and at 6 and 12 months after, using a maximum exercise test on a treadmill (modified Balke protocol).The patients were randomized after surgery to a control group (n=188, usual care) or an intervention group (n=187) stratified by menopausal status. The 12 months exercise intervention program started 2-3 weeks after surgery and the patients received a detailed training program based on their own VO2max at baseline. They met for training sessions in groups of 10-12 women for 60 minutes twice a week during a 12 month period, and were in addition asked to perform at least 120 minutes of exercise at home (a total of 240 minutes of exercise weekly).Analyses were done on an intention-to-treat basis (NCT02240836). Preliminary results: Breast cancer patients (n=375) with a mean age at diagnosis of 55.2 years (27.0-75.0 years) had a mean body mass index (BMI) of 25.1kg/m2, a mean VO2max before surgery of 31.5 ml•min−1•kg−1, and 57 % of the patients underwent chemotherapy (paclitaxel, epirubicin/cyclophosphamide based adjuvant chemotherapy). Comparing the intervention group to the control group, the intervention group had a decrease in VO2max of 2.7% after 6 months, but they improved their VO2max by 2.3 % at 12 months compared to before surgery (p=0.001). Breast cancer patients in the control group had a 10 % reduction in VO2max 6 months after surgery (p Conclusion: Our findings strongly support that tailored exercise training during adjuvant breast cancer treatment may counteract a decline in cardiovascular function, and in particular among those receiving chemotherapy. Our study supports incorporation of supervised clinical exercise programs into breast cancer treatment guidelines. Final results of the trial at SABCS 2018 (the trial closes October 15, 2018) total included N=539 (NCT02240836) Citation Format: Thune I, Husoy A, Frydenberg H, Flote VG, Fjeldheim F, Bertheussen GF, Lundgren S, Lomo J, Wist EA, McTiernan A, Schlichting E. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS5-02.","PeriodicalId":12697,"journal":{"name":"General Session Abstracts","volume":"47 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General Session Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.SABCS18-GS5-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Background: Breast cancer survival rates have improved, but cardiovascular disease is a competing cause of death among breast cancer survivors, and treatment-induced cardio-toxicity remains a major concern. The effect of aerobic exercise on cardiovascular function during adjuvant breast cancer treatment is not yet well established. Material & methods: The women participating in the Energy Balance and Breast Cancer Aspect (EBBA)-II trial are aged 18-75 years and diagnosed with stage I-II breast cancer. VO2max was assessed at three separate times, prior to surgery and at 6 and 12 months after, using a maximum exercise test on a treadmill (modified Balke protocol).The patients were randomized after surgery to a control group (n=188, usual care) or an intervention group (n=187) stratified by menopausal status. The 12 months exercise intervention program started 2-3 weeks after surgery and the patients received a detailed training program based on their own VO2max at baseline. They met for training sessions in groups of 10-12 women for 60 minutes twice a week during a 12 month period, and were in addition asked to perform at least 120 minutes of exercise at home (a total of 240 minutes of exercise weekly).Analyses were done on an intention-to-treat basis (NCT02240836). Preliminary results: Breast cancer patients (n=375) with a mean age at diagnosis of 55.2 years (27.0-75.0 years) had a mean body mass index (BMI) of 25.1kg/m2, a mean VO2max before surgery of 31.5 ml•min−1•kg−1, and 57 % of the patients underwent chemotherapy (paclitaxel, epirubicin/cyclophosphamide based adjuvant chemotherapy). Comparing the intervention group to the control group, the intervention group had a decrease in VO2max of 2.7% after 6 months, but they improved their VO2max by 2.3 % at 12 months compared to before surgery (p=0.001). Breast cancer patients in the control group had a 10 % reduction in VO2max 6 months after surgery (p Conclusion: Our findings strongly support that tailored exercise training during adjuvant breast cancer treatment may counteract a decline in cardiovascular function, and in particular among those receiving chemotherapy. Our study supports incorporation of supervised clinical exercise programs into breast cancer treatment guidelines. Final results of the trial at SABCS 2018 (the trial closes October 15, 2018) total included N=539 (NCT02240836) Citation Format: Thune I, Husoy A, Frydenberg H, Flote VG, Fjeldheim F, Bertheussen GF, Lundgren S, Lomo J, Wist EA, McTiernan A, Schlichting E. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS5-02.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
GS5-02:运动训练对乳腺癌辅助治疗期间心血管功能的影响。EBBA-II试验结果
背景:乳腺癌生存率有所提高,但心血管疾病是乳腺癌幸存者死亡的一个竞争原因,治疗引起的心脏毒性仍然是一个主要问题。在乳腺癌辅助治疗期间,有氧运动对心血管功能的影响尚未得到很好的证实。材料与方法:参与能量平衡与乳腺癌方面(EBBA)-II试验的女性年龄为18-75岁,诊断为I-II期乳腺癌。在手术前和手术后6个月和12个月,使用跑步机上的最大运动测试(改进的Balke方案),分别在三个不同的时间评估VO2max。术后患者按绝经状况随机分为对照组(n=188,常规护理组)和干预组(n=187)。12个月的运动干预计划在手术后2-3周开始,患者根据自己的基线VO2max接受详细的训练计划。在12个月的时间里,她们以10-12名女性为一组,每周进行两次60分钟的训练,此外还被要求在家进行至少120分钟的锻炼(每周总共240分钟的锻炼)。在意向治疗基础上进行分析(NCT02240836)。初步结果:乳腺癌患者(n=375),诊断时平均年龄为55.2岁(27.0 ~ 75.0岁),平均体重指数(BMI)为25.1kg/m2,术前平均VO2max为31.5 ml•min - 1•kg - 1, 57%的患者接受了化疗(紫杉醇、表柔比星/环磷酰胺辅助化疗)。干预组与对照组比较,干预组6个月后VO2max下降2.7%,但12个月时VO2max较术前提高2.3% (p=0.001)。对照组乳腺癌患者在手术后6个月的VO2max降低了10% (p结论:我们的研究结果强烈支持在辅助乳腺癌治疗期间量身定制的运动训练可以抵消心血管功能的下降,特别是在接受化疗的患者中。我们的研究支持将有监督的临床锻炼项目纳入乳腺癌治疗指南。SABCS 2018的最终结果(试验于2018年10月15日结束)总计包括N=539 (NCT02240836)。引文格式:Thune I, Husoy A, Frydenberg H, Flote VG, Fjeldheim F, Bertheussen GF, Lundgren S, Lomo J, Wist EA, McTiernan A, Schlichting E.心血管功能和运动训练对乳腺癌辅助治疗的影响。EBBA-II试验结果[摘要]。2018年圣安东尼奥乳腺癌研讨会论文集;2018年12月4-8日;费城(PA): AACR;癌症杂志,2019;79(4增刊):摘要nr GS5-02。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group Abstract GS3-07: Identifying patients whose symptoms are under-recognized during breast radiotherapy: Comparison of patient and physician reports of toxicity in a multicenter cohort Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients Abstract GS5-01: A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab Abstract GS4-02: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1